Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Powershares Db Multi-Sector Commodi Powershares Db Oil Fund
DBO
5
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
US Stock MarketDetailed Quotes
BridgeBio Pharma (BBIO)
- 67.610
- +0.280+0.42%
Close Jun 5 15:59 ET
- 67.610
- 0.0000.00%
Post 20:01 ET
13.24BMarket Cap-18.08P/E (TTM)
69.510High66.590Low2.59MVolume67.450Open67.330Prev Close176.08MTurnover1.70%Turnover RatioLossP/E (Static)195.86MShares84.94052wk High-5.81P/B10.33BFloat Cap38.57552wk Low--Dividend TTM152.72MShs Float84.940Historical High--Div Yield TTM4.34%Range %4.980Historical Low67.982Avg Price1Lot Size
BridgeBio Pharma (BBIO) News
Leidos, BridgeBio, T1 Energy, Ecopetrol, Medtronic Trending
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157
Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
CCORF Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $104
Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82
Analysts Conflicted on These Healthcare Names: Tempus AI, Inc. Class A (TEM), Tyra Bioscience (TYRA) and BridgeBio Pharma (BBIO)
BridgeBio, Dave, Marvell, Filana, GE Trending With Analysts
BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110
Analysts Are Bullish on These Healthcare Stocks: Bristol-Myers Squibb (BMY), BridgeBio Pharma (BBIO)
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $110 Price Target
Morgan Stanley Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $98
William Blair Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP)
BridgeBio Gains as Muscular Dystrophy Therapy Gets FDA Priority Review
BridgeBio Announces FDA Acceptance Of Its New Drug Application With Priority Review For Oral BBP-418 For The Treatment Of Individuals Living With Limb-Girdle Muscular Dystrophy Type 2I/R9; FDA Sets PDUFA Date Of November 27
Express News | BridgeBio Announces FDA Acceptance and Priority Review of Nda for Bbp-418 for Lgmd2I/R9
Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing
BridgeBio Pharma Shares Fall After Raymond James Downgrade
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On June 3, Eastern Time, the U.S. House of Representatives passed a resolution limiting Trump's authority to use military force against Iran
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm